Invention Grant
- Patent Title: Treatment of cancer using hypoxia activated prodrugs
- Patent Title (中): 使用缺氧活化前药治疗癌症
-
Application No.: US13125303Application Date: 2009-10-21
-
Publication No.: US08946275B2Publication Date: 2015-02-03
- Inventor: John G. Curd , Stewart Kroll , Mark Matteucci , Charles P. Hart , Jian-Xin Duan
- Applicant: Stewart Kroll , Mark Matteucci , Charles P. Hart , Jian-Xin Duan , Karen Curd
- Applicant Address: US CA South San Francisco
- Assignee: Threshold Pharmaceuticals, Inc.
- Current Assignee: Threshold Pharmaceuticals, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Kilpatrick Townsend & Stockton LLP
- International Application: PCT/US2009/061541 WO 20091021
- International Announcement: WO2010/048330 WO 20100429
- Main IPC: A01N57/00
- IPC: A01N57/00 ; A61K31/675 ; A01N57/26 ; A61K31/66 ; A61K9/00 ; A61K31/337 ; A61K31/4985 ; A61K31/513 ; A61K31/555 ; A61K31/704 ; A61K31/7068 ; A61K33/24 ; A61K45/06 ; A61K47/26 ; A61K31/519

Abstract:
Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
Public/Granted literature
- US20130202716A1 Treatment of Cancer Using Hypoxia Activated Prodrugs Public/Granted day:2013-08-08
Information query